Pentamidine for Injection (Benambax) is an anti-infective drug specifically used for the treatment of Pneumocystis jirovecii pneumonia (PCP). Its main active ingredient is pentamidine isethionate.
How to Use Pentamidine for Injection (Benambax)
Multiple Routes of Administration
Intravenous Infusion: Dissolve the drug in 3-5 mL of Japanese Pharmacopoeia Water for Injection first, then dilute it with 50-250 mL of Japanese Pharmacopoeia Glucose Injection or Normal Saline, and complete the infusion within 1-2 hours.
Intramuscular Injection: Dissolve the drug in 3 mL of Japanese Pharmacopoeia Water for Injection, then administer it as a deep intramuscular injection at 2 or more different sites.
Inhalation Administration: Dissolve 300-600 mg of the drug in 3-5 mL of Japanese Pharmacopoeia Water for Injection, and administer inhalation treatment for 30 minutes using an ultrasonic nebulizer or a compressed nebulizer that can generate aerosol particles of 5 μm or smaller.
Standard Dosage Setting
The convention recommended dosage is 4 mg/kg per day (calculated as pentamidine isethionate), administered once daily.
The specific administration plan must be accurately calculated based on the patient's body weight and implemented under the supervision of a doctor.
Medication Monitoring for Pentamidine for Injection (Benambax)
Treatment Cycle Management
The treatment cycle should generally not exceed 14 days.
If it is necessary to extend the treatment, the balance between the risks of side effects (such as renal function damage) and the therapeutic benefits must be strictly evaluated.
Special Monitoring Requirements
Blood Glucose Monitoring: Closely monitor changes in blood glucose during and after treatment.
Electrocardiogram Monitoring: Prevent the risks of QT interval prolongation and arrhythmia.
Renal Function Monitoring: Include indicators such as serum creatinine and blood urea nitrogen.
Liver Function Monitoring: Regularly test indicators such as transaminases.
Medication for Special Populations with Pentamidine for Injection (Benambax)
Patients with Renal Impairment
The use of this drug in patients with renal impairment may lead to further deterioration of renal function and increase the risk of adverse reactions. Enhanced monitoring and timely dosage adjustment are required.
Patients with Hepatic Impairment
Patients with hepatic impairment should use this drug with caution, as it may worsen liver damage and increase the incidence of adverse reactions.
Pregnant and Lactating Women
Pregnant Women: The balance between therapeutic benefits and risks must be strictly evaluated before using this drug in pregnant women. It should be used only when the benefits are clearly greater than the risks.
Lactating Women: Lactating women need to comprehensively consider the therapeutic benefits and the benefits of breastfeeding to decide whether to continue breastfeeding or discontinue treatment.
